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Abstract 
Metabolomics is the quantification of small molecules, commonly 
known as metabolites. Collectively, these metabolites and their 
interactions within a biological system are known as the metabolome. 
The metabolome is a unique area of study, capturing influences from 
both genotype and environment. The availability of high-throughput 
technologies for quantifying large numbers of metabolites, as well as 
lipids and lipoprotein particles, has enabled detailed investigation of 
human metabolism in large-scale epidemiological studies. The Born in 
Bradford (BiB) cohort includes 12,453 women who experienced 13,776 
pregnancies recruited between 2007-2011, their partners and their 
offspring. In this data note, we describe the metabolomic data 
available in BiB, profiled during pregnancy, in cord blood and during 
early life in the offspring. These include two platforms of metabolomic 
profiling: nuclear magnetic resonance and mass spectrometry. The 
maternal measures, taken at 26-28 weeks’ gestation, can provide 
insight into the metabolome during pregnancy and how it relates to 
maternal and offspring health. The offspring cord blood 
measurements provide information on the fetal metabolome. These 
measures, alongside maternal pregnancy measures, can be used to 
explore how they may influence outcomes. The infant measures 
(taken around ages 12 and 24 months) provide a snapshot of the early 
life metabolome during a key phase of nutrition, environmental 
exposures, growth, and development. These metabolomic data can be 
examined alongside the BiB cohorts’ extensive phenotype data from 
questionnaires, medical, educational and social record linkage, and 
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Introduction
Metabolomics is the quantification of small molecules result-
ing from metabolic processes. The metabolome is influenced 
by both genotype and environment, and dynamically responds 
to environmental influences. Developments in high-throughput 
technologies have allowed the efficient and accurate quanti-
fication of metabolites. This has revolutionised our ability to 
understand the causes and consequences of variation in human 
metabolism, and the contribution that multiple metabolites 
can make to risk prediction, using large-scale epidemiological 
studies1–4. Lipids and lipoproteins, which are measured in most 
high-throughput platforms used in epidemiology, are larger 
than the threshold used to define metabolites (<1.5k Daltons) 
and are therefore metabolomic traits. For simplicity in this 
paper we refer to these as metabolites.
Birth cohorts can be useful for exploring prenatal influences 
on birth and later life outcomes. Recently, studies have shown 
metabolomic profiling can aid us in our understanding of 
maternal health during pregnancy3–5 and of the influence of 
in utero exposures on subsequent offspring health6,7. The Born 
in Bradford (BiB) study is a UK longitudinal birth cohort8. 
Nuclear magnetic resonance (NMR) and mass spectrom-
etry (MS) data are available in BiB including measurements 
during pregnancy, cord blood and early life in the offspring. 
MS offers a truly untargeted approach with comprehensive 
coverage of the metabolome (>1,000 metabolites) due to its 
high sensitivity. However, MS only provides relative quantifica-
tion based on peak area in these approaches without comparison 
to a metabolite reference standard. NMR offers less coverage 
of the metabolome, but with absolute quantification possible 
in clinically meaningful units (e.g. mmol/L).
The range of metabolomics data in BiB, coupled with the 
substantial data obtained through questionnaires, research clinic 
assessments, linkage to medical records, educational and social 
records, genome wide (mothers, offspring and a subgroup of 
fathers) and epigenome wide (mother and offspring) profil-
ing makes BiB a valuable resource for metabolomics research. 
This data note describes the metabolomics data currently avail-
able in BiB - how these were obtained, quantified, utilised, 
as well as potential future uses, strengths and limitations. 
Figure 1 provides an illustrative summary of which type of 
metabolomic data have been collected on which cohort par-
ticipants and when, up to 2020. Planned further metabolomic 
data collection is also described (see Using the BiB 
metabolomic data).
Methods
Ethical approval and consent
Ethical approval for the study was granted by the Bradford 
National Health Service Research Ethics Committee (ref 
Figure 1. Summary illustration of the Born in Bradford metabolomics data. NMR, nuclear magnetic resonance; MS, mass 
spectrometry; EDTA, ethylenediaminetetraacetic acid.
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06/Q1202/48), and all participants gave written informed 
consent. The ALL IN sub-study had ethical approval from 
the London School of Hygiene & Tropical Medicine ethics 
committee (ref: 5320) and the Bradford Research Ethics 
committee (ref: 08/H1302/21). Parents (usually the mother) gave 
informed, written consent to take part in the study.
Cohort
The BiB study is a population-based prospective birth cohort. 
In total, 12,453 women who experienced 13,776 pregnancies 
were recruited at their oral glucose tolerance test (OGTT) at 
approximately 26–28 weeks’ gestation, which was offered to 
all women booked for delivery at Bradford Royal Infirmary 
(BRI). Eligible women had an expected delivery between 
March 2007 and December 2010. The study is unique because 
it includes high proportions of White European and South 
Asian families, all residing in Bradford, UK. Bradford is 
a city in the North of England with high levels of socio-
economic deprivation, and the cohort was started due to a 
high prevalence of poor child health in the city8. Full details of 
the study methodology were reported previously8. The study 
website provides more information, including protocols, ques-
tionnaires and information on how researchers can access 
data and a full list of all available data. Mothers and their 
partners, who were recruited into the study, provided detailed 
interview questionnaire data, measurements, and biological 
samples. They also consented to the linkage of their and their 
child’s data to routine (primary and secondary care) health 
and education data.
Blood sampling
Maternal overnight-fasted blood was taken during the OGTT 
and processed and stored at -80°C for further research and 
analyses. Infant cord blood samples were taken whenever 
possible (i.e. so long as staff were available, and collection 
of an umbilical vein sample did not interfere with care of the 
mother or infant) and immediately processed and stored 
at -80°C. Samples were taken in a subgroup of offspring 
in early childhood for a specific project on childhood viral 
infection9. We describe the processes of taking, processing, 
and storing samples at each time point before moving on to 
describe the NMR and MS metabolomic profiling.
Pregnancy blood samples. Of the 13,776 pregnancies in the 
BiB cohort, 11,480 had a fasting blood sample taken during 
the OGTT (n = 10,574 [92%] between 26–28 weeks’ gestation, 
with the remaining women being within 11–39 weeks’ gesta-
tion). Samples were taken by trained phlebotomists working 
in the antenatal clinic of the BRI and sent immediately to the 
hospital laboratory.
Venous blood was collected in GEL tubes to obtain serum 
and plasma. The following processing steps were undertaken 
prior to storage at -80°C.
1)      Storage racks were prepared.
2)      Participant details were checked, making sure that both 
the BiB study ID and hospital number on the speci-
men bottles matched those on the participant tracking 
forms.
3)      Tubes were centrifuged at 3500 rpm for 10 minutes 
at room temperature.
4)       A 1 ml automatic pipette was used to aliquot samples 
into 2 × 1.5 ml vials.
5)      Vials were labelled with appropriate BiB study labels 
and the duplicate barcode label was placed in the 
corresponding space marked on BiB tracking form.
6)      Aliquots (n = 3) were then placed in racks in a 
-80°C freezer.
All samples were processed within 2.5 hours and then placed 
in −80°C freezers. There were no freeze-thaw events of 
the samples prior to their use for the pregnancy metabolomic 
profiling. Serum samples were used for NMR metabolomic 
profiling, except for five (0.04%) samples which were plasma. 
For MS pregnancy metabolomics, ethylenediaminetetraacetic 
acid (EDTA) (a sample tube anticoagulant) plasma samples 
were used. Previous work has shown that reproducibility in 
both serum and plasma is good. As long as the same blood 
sample procedures are used (as in BiB), either matrix should 
yield similar results10.
Cord blood samples. Venous cord blood samples were all 
obtained at delivery by the attending midwife at the BRI, 
following research protocols. Cord blood sampling was not 
attempted for women delivering outside of the BRI, if the 
attending midwife was too busy, or if attempting to collect 
a research cord blood sample would interfere with postnatal 
care. Samples were refrigerated at 4°C in EDTA tubes until 
collected by BRI laboratory staff within 12 hours. Samples 
were then spun, frozen and stored at −80°C. In total, 
the BiB study collected 9,604 cord blood EDTA plasma 
samples. There were no freeze-thaw events of the cord blood 
samples.
Infant blood samples. Infant metabolomics were performed 
on blood samples that were collected on a subsample of the 
BiB cohort; those enrolled into the Allergy and Infection 
Study (ALL IN)9. Children enrolled in the BiB cohort, and 
born on or after 1 March 2008 with a maternal baseline 
questionnaire were eligible to take part in ALL IN. Moth-
ers were invited to participate in ALL IN one month before 
their child’s first birthday. A questionnaire was completed by 
those who consented, and a 5ml venous blood sample was 
taken from the child, centrifuged, and stored at -80°C. This 
was repeated one year later to provide questionnaire data and 
serum from a ~12-month visit (mean age of 14 months, ranging 
from 9–18 months) and a ~24-month visit (mean age of 
26 months, ranging from 23–33 months). Trained community 
research administrators (CRAs) recruited participants, obtained 
consent, and collected data, including blood samples, at each 
visit. They received training in phlebotomy and were assessed 
by the senior paediatric phlebotomist at the BRI. Ametop 
cream or Cryogesic spray were used to anaesthetise the 
venepuncture site. Only two attempts at venepuncture were 
permitted for each child. There was a fridge in the clinic for 
storing bloods before transfer to the lab. The blood samples 
taken on home visits were kept in a cool bag with an 
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ice pack and then taken straight to the laboratory at BRI 
within 1–2 hours. The times of each step (blood taken, arrived 
at lab, centrifuged, aliquoted, frozen) were recorded on the 
blood form and were entered onto a database (so that research-
ers can check distribution of times if needed). For home or 
clinic visits outside normal working hours, the CRA who took 
the blood sample would centrifuge the blood at the lab and 
leave it in the lab fridge for processing the next day. All infant 
metabolomics were performed on serum samples. There was a 
maximum of two freeze-thaw events prior to metabolomics 
analyses of the infant samples.
Metabolomic datasets in BiB
There are six metabolomics datasets including different 
populations and timepoints available in BiB. These are described 
below and summarized in Table 1 and Figure 1. We have 
divided the methods between the two main platforms (NMR 
and MS). We describe the methods used to generate each 
dataset and use flow charts to illustrate how selection was 
performed.
NMR metabolomics
NMR methods. We describe the NMR methods which apply 
to all the NMR datasets described in Table 1. Profiling of 
circulating lipids, fatty acids, and metabolites was done by a 
high-throughput targeted NMR platform (Nightingale Health© 
(Helsinki, Finland)) at the University of Bristol, providing 
quantitative information on 227 metabolic traits (including ratios 
and other traits derived from the quantified NMR spectra)1. 
Details of all 227 traits can be found in the Extended 
data11.
The Nightingale NMR metabolite quantification was achieved 
through measurements of three molecular windows from each 
serum/plasma sample. Two of the spectra (LIPO and LMWM 
windows) are acquired from native serum/plasma and one 
spectrum from serum lipid/plasma extracts (LIPID window). 
The NMR spectra are measured using Bruker AVANCE III 
spectrometer operating at 600 MHz. Measurements of native 
serum/plasma samples and serum/plasma lipid extracts are 
conducted at 37°C and 22°C, respectively.
The NMR spectra were analysed for metabolite quantifica-
tion (molar concentrations) in an automated fashion. For each 
metabolite, a ridge regression model was applied for quan-
tification to overcome the problems of heavily overlapping 
spectral data. In the case of the lipid data, quantifica-
tion models were calibrated using high-performance 
liquid chromatography methods, and individually cross-validated 
against NMR-independent lipid data. Low-molecular-weight 
metabolites, as well as lipid extract measures, were quantified 
as mmol/L based on regression modelling calibrated against 
a set of manually fitted metabolite measures. The calibration 
data were quantified based on iterative line-shape fitting 
analysis using PERCH NMR software (PERCH Solutions 
Ltd., Kuopio, Finland). Quantification could not be directly 
established for the lipid extract measures due to experimental 
variation in the lipid extraction protocol. Therefore, serum/plasma 
lipid extract were scaled to total a standard serum cholesterol 
sample from the LIPO spectrum.
Validation of the NMR platform. Quality control (QC) of the 
data were undertaken by Nightingale Health© prior to 
returning metabolite concentrations to BiB. Their QC procedures 
Table 1. Metabolomics datasets in the BiB cohort separated by platform.
# Data source Brief description
Nuclear magnetic resonance
1 Pregnancy NMR – Dataset 1 N = 11,480 pregnancies. Single timepoint using maternal serum taken from a fasted blood sample 
around 26–28 weeks’ gestation. Of the 11,480, 37% are White British (40% White European) mothers 
and 44% Pakistani (49% South Asian).
2 Cord blood NMR – Dataset 2 N = 7,980 children. Single timepoint using cord blood, EDTA plasma. 
3 Infants NMR (aged 12 or 24 
months) – Dataset 3
N = 2,108 at either 12- or 24-months using serum samples. 
N = 1,690 at 12 months. 
N = 1,536 at 24 months. 
N = 1,118 at both timepoints. 
Mass Spectrometry
4 Pregnancy MS – Dataset 1a N = 1,000 pregnancies. Single timepoint using EDTA plasma taken from a fasted blood sample 
between 26–28 weeks’ gestation. Of the 1,000, 50% are White British and the other 50% are Pakistani 
ethnicity. 
5 Cord blood MS – Dataset 1b N = 1,000 children (paired with women from Dataset 1a). Single timepoint using cord blood, EDTA 
plasma. 
6 Pregnancy MS – Dataset 2 N = 2,000 pregnancies within a case-cohort design. EDTA plasma sample taken between 26–28 weeks’ 
gestation. Of the 2,000 women, 47% are White British and 53% are Pakistani.
NMR, nuclear magnetic resonance; MS, mass spectrometry; EDTA, ethylenediamine tetraacetic acid.
Page 5 of 18
Wellcome Open Research 2020, 5:264 Last updated: 05 NOV 2020
check various issues related to the sample integrity and the 
biomarker quantification. QC reports for the NMR datasets 
can be found in the Extended data11.
We also undertook validation of some of the NMR measures 
by comparing concentrations of fasting glucose, total 
cholesterol, high-density lipoprotein cholesterol (HDLc), low-
density lipoprotein cholesterol (LDLc), and triglycerides from 
the NMR platform to the same measures from the same samples 
assessed by clinical chemistry measurements (Figure 2). Clini-
cal chemistry measurements were completed at the BRI labo-
ratory (fasting glucose) or Glasgow Royal Infirmary (lipids). 
Figure 2. Comparison of glucose (2A), total cholesterol (2B), high-density lipoprotein cholesterol (2C), low-density lipoprotein cholesterol 
(2D) and triglycerides (2E) concentrations between Nightingale Health© nuclear magnetic resonance (NMR) (x-axis) and routine clinical 
chemistry assays (y-axis) (N= 11,036 to 11,337). R = Pearson correlation coefficient.
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Glucose was measured using a glucose oxidase method 
that does not cross-react with insulin. Total cholesterol, 
HDLc and triglycerides were measured following the stand-
ard Lipid Research Clinics Protocol using enzymatic reagents. 
LDLc was estimated from total cholesterol, HDLc and trig-
lycerides (LDLc = [Total cholesterol in mmol/l] – [HDLc in 
mmol/l] – [Triglycerides in mmol/l ÷ 2.2]). The correlation 
between fasting glucose measured by clinical chemistry and 
by NMR was 0.73 and for all four lipids was between 0.85 
and 0.93, with the intercepts of the regression line close 
to zero for HDLc, LDLc, and triglycerides, but higher for 
glucose (1.85) and total cholesterol (1.21). This suggests that 
the NMR platform systematically underestimates glucose and 
total cholesterol levels. However, the high levels of correlation, 
particularly for the lipid measures, is reassuring and suggests 
association analyses would have validity. To further test the 
validity of the NMR measures, we compared associations 
of maternal early pregnancy body mass index (BMI), treated 
as an exposure, with fasting glucose, and the four lipid meas-
ures from clinical chemistry and NMR as the outcome. 
We also compared associations between the five metabolic 
measures (from clinical chemistry and NMR) as exposures, with 
hypertensive disorder of pregnancy (HDP; either gestational 
hypertension or pre-eclampsia, defined on the basis of inter-
national criteria applied to all measures of blood pressure and 
proteinuria extracted from clinical records)12 as the outcome. 
Associations of BMI with the five outcomes were direction-
ally consistent between clinical chemistry and NMR measure-
ments. However, the NMR associations were weaker (closer 
to the null) and there were clear differences in magnitudes of 
association between the two methods for the associations of 
BMI with glucose and HDLc (Figure 3A). By contrast, results 
were concordant between the two methods for the associations 
of metabolites with odds ratios of HDP (Figure 3B).
Participant selection and characteristics of those with NMR 
data. In this subsection, we present flow charts to illustrate selec-
tion and inclusions into the NMR participant groups (Figure 4) 
and describe participant characteristics for the BiB NMR 
datasets (Table 2). All three of the samples of BiB participants 
with NMR data (maternal pregnancy N = 11,480, offspring 
cord blood N = 7,980, and offspring 12–24 months N = 2,108) 
had very similar distributions of maternal age, parity, early 
pregnancy BMI, residential area deprivation, offspring sex 
and birth weight to those seen in the whole cohort of 13,776 
participants (Table 2).
Mass spectrometry metabolomics
Mass spectrometry methods. The untargeted MS metabo-
lomics analysis of over 1,000 metabolites was performed at 
Metabolon, Inc. (Durham, North Carolina, USA). Samples 
were sent to Metabolon in two separate batches. Dataset 1 was 
completed in December 2017 and consisted of 1,000 maternal 
pregnancy samples and 1,000 offspring paired cord blood 
samples. Dataset 2 was completed in December 2018 and 
consisted of 2,000 maternal pregnancy samples.
At Metabolon, samples were managed by a laboratory 
information management system and were kept at -80°C. 
Recovery standards were added to samples prior to monitor the 
extraction process. To remove proteins, dissociate small mol-
ecules bound to proteins, disassociate molecules trapped in the 
precipitated protein matrices, and to recover chemically diverse 
metabolites, proteins were precipitated with methanol under 
vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) fol-
lowed by centrifugation. The resulting extract was divided 
into five fractions: two for analysis by two separate reverse 
phase ultra-high-performance liquid chromatography-tandem 
mass spectrometry (UPLC-MS/MS) methods with positive 
ion mode electrospray ionization (ESI), one for analysis by 
reverse phase UPLC-MS/MS with negative ion mode ESI, one 
for analysis by hydrophilic interactive liquid chromatography 
(HILIC)/UPLC-MS/MS with negative ion mode ESI, and 
one sample was reserved for backup. Samples were placed 
on a TurboVap® (Zymark) to remove the organic solvent. 
The sample extracts were stored overnight under nitrogen 
before preparation for analysis. The four independent 
UPLC-MS/MS methods provide relative quantification of >1,000 
metabolites in 10 key classes: amino acids, carbohydrates, lip-
ids, nucleotides, microbiota metabolism, carbon metabolism, 
energy, cofactors & vitamins, xenobiotics, and unidentified 
metabolites. A list of metabolites defined in each of the 
datasets can be found in the Extended data11. Metabolite 
concentrations were quantified using area-under-the-curve of 
primary MS ions and were expressed as the means of the 
medians (MoM) value for all batches processed on the given 
day.
Validation of the MS platform. Details of the Metabolon QC 
procedures and data quality for the Metabolon BiB datasets 
are described in the reports found in the Extended data11. In 
brief, procedures were conducted to: (i) assure that all aspects 
of the Metabolon process are operating within specifications, 
(ii) assess the effect of a non-plasma matrix on the Metabo-
lon process and distinguish biological variability from proc-
ess variability, (iii) assess the contribution to compound signals 
from the process (using Process Blank) and (iv) segregate 
contamination sources in the extraction (using Solvent Blank).
As an additional data QC, we explored correlations between 
MS and both NMR and clinical chemistry fasting glucose 
measures (glucose is the only common trait we have data 
on for MS, NMR, and clinical chemistry). Pearson’s correla-
tion coefficient comparing MS to clinical chemistry (0.65) 
was modest and lower than that for NMR (0.73, see above 
and Figure 2) and the intercept was 0.11 (Figure 5A). Cor-
relation between Metabolon and NMR was higher (0.77) and 
the intercept was 0.10 (Figure 5B).
Participant selection and characteristics of those with MS 
data. The flow of participants into the MS datasets are 
illustrated in Figure 6, and the characteristics of participants 
included in the two MS datasets provided in Table 3. Only 
women of either Pakistani or White British ethnic background 
were included in the MS datasets because, due to cost, we were 
only able to do this on a subset of the cohort. As these two 
groups represent ~85% of BiB it was felt the numbers for any 
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Figure 3. Comparisons of the associations of early pregnancy body mass index (BMI) with fasting glucose and lipids measured by 
Nightingale Health© nuclear magnetic resonance (NMR) and routine clinical chemistry assays (3A), fasting glucose and lipids measured 
by Nightingale Health© NMR and routine clinical chemistry assays with hypertensive disorder of pregnancy (HDP) (3B). Associations in 
3A are from unadjusted linear regression and data points show standard deviation differences in mean metabolite per one standard 
deviation (1SD) higher BMI. Associations in 3B are from unadjusted logistic regression and data points show unadjusted odds ratios 
for HDP per 1SD higher in metabolic trait. Error bars = 95% confidence intervals.
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other group would be too small for meaningful analyses. In 
Dataset 1, 1,000 women were selected on the basis that they 
had stored fasting plasma, a useable cord blood sample, genome 
wide data on both mother and offspring and were either of 
White British or Pakistani origin (Figure 6A). Following 
these inclusions, 500 women were selected at random from 
each ethnic group (White British and Pakistani). In Dataset 2, 
a case-cohort design was used13,14. A case-cohort design con-
sists of a cohort with an over-sampling of all cases. The BiB 
case-cohort consists of 2,000 women (only pregnancy sam-
ples were assayed in Dataset 2). As with Dataset 1, women were 
selected based on certain characteristics shown in Figure 6B, 
including that they had not already had Metabolon MS analyses. 
From those who fulfilled these pre-specified criteria, six groups 
of cases were selected: women with (a) gestational diabetes; 
(b) gestational hypertension; (c) pre-eclampsia; (d) preterm 
birth; (e) congenital anomaly; (f) stillbirth. In total, 801 women 
had experienced one or more of these conditions. Having 
selected all cases these were then replaced into the eligi-
ble cohort and a sub-cohort of 1,199 women were randomly 
selected from the eligible cohort. Thus, the comparison group 
in this case-cohort study is representative of the eligible cohort 
Figure 4. Illustrating the flow of participants into the NMR datasets in the Born in Bradford cohort. Figure 4A shows the maternal 
pregnancy (Dataset 1: NMR metabolomics at 26–28 weeks’ gestation) and offspring cord blood samples (Dataset 2: NMR metabolomics 
taken from the umbilical vein shortly after delivery). Figure 4B shows the offspring 12–24 months NMR metabolomic sample (Dataset 3). 
Abbreviations: NMR, nuclear magnetic resonance; BiB, Born in Bradford; ALL IN, Allergy and Infection study.
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(i.e. the cohort comparison group includes some of the 
cases in proportions that would reflect the whole cohort). 
The final BiB case-cohort sample consists of three groups 
(Figure 6B): 1) selected as comparison group (N = 1,199), 
2) selected as cases only (N = 408), and 3) selected as a case 
and control (N = 393). The comparison group in any analyses 
will vary depending on the research question.
For the MS dataset, researchers are given the option of 
using the ‘raw’ data from Metabolon or a quantified (scaled) 
data set, in which missing data have been imputed and 
the multiple of median values transformed to standard deviation- 
(z-) scores (by subtracting the sample mean value for each metab-
olite from the participant value and then dividing by the sample 
standard deviation for that metabolite). This transforma-
tion helps overcome the problem of high missing data in 
metabolomics15. This cohort for MS profiling were sampled 
on their ethnicity. It is almost 50% White British and Pakistani 
(there are slightly more Pakistani women in Dataset 2), as 
opposed to around 15% of the whole BiB cohort not 
belonging to either of these ethnic groups. However aside from 
this, the sample is representative of the whole cohort (Table 3).
Overlap between metabolomics datasets
Having participants in multiple datasets (i.e. maternal preg-
nancy, offspring cord, offspring 12–24 months) and across the 
two metabolomic platforms provides scope for unique research 
opportunities. Figure 7 illustrates the overlap between BiB 
Table 2. Participant characteristics for NMR datasets in the BiB cohort.
Maternal 
pregnancy NMR 
dataset (n=11,480)
Offspring cord 
blood NMR 
dataset (n=7,890)
Offspring 12- or 24-
months NMR dataset 
(n = 2,108)
BiB cohort 
(n=13,776)
Characteristics Unit / Category  
Maternal Age
Years 
Missing
27.3 (5.6) 
410 (3.6)
27.5 (5.6) 
627 (7.9)
28.3 (5.7) 
60 (2.9)
27.3 (5.6) 
1445 (10.5)
Maternal Parity
Nulliparous 
Multiparous 
Missing
4310 (37.5) 
6428 (55.9) 
742 (6.5)
2765 (36.6) 
5125 (65.0) 
344 (4.4)
819(39.9) 
1,233(58.4) 
56 (2.7)
5101 (37.0) 
7773 (56.4) 
902 (6.5)
Maternal BMI
kg/m2 
Missing
26.1 (5.7) 
2160 (18.8)
26.2 (5.7) 
1464 (18.5)
26.2(5.5) 
106 (5.0)
26.0 (5.7) 
3281 (23.8)
Maternal ethnicity
White British 
Pakistani 
Other 
Missing
4268 (37.2) 
4995 (43.5) 
1887(16.4) 
330 (2.4)
2902 (37.7) 
3596 (46.7) 
1206 (15.7) 
186 (2.4)
769 (49.7) 
1048 (49.7) 
291 (13.8) 
0
5055 (37.8) 
6088 (45.5) 
2223 (16.6) 
410 (3.0)
Index of multiple 
deprivation
Quintile 1 (most deprived) 
Quintile 2 
Quintile 3 
Quintile 4 
Quintile 5 (least deprived) 
Missing
6646 (65.9) 
1830 (18.2) 
1124 (11.2) 
306 (3.0) 
173 (1.7) 
1401 (12.2)
4439 (65.8) 
1220 (18.1) 
778 (11.5) 
187 (2.8) 
118 (1.8) 
1148 (14.6)
1400(66.4) 
355 (16.8) 
248 (11.8) 
70 (3.3) 
34(1.6) 
1 (0.0)
7566 (66.4) 
2052 (18.0) 
1250 (11.0) 
334 (2.9) 
190 (1.7) 
2384 (17.3)
Offspring sex
Male 
Female 
Missing
5705 (49.7) 
5420 (48.7) 
355 (3.1)
4095 (51.9) 
3795 (48.1) 
3 (0.0)
1065(50.2) 
1029(48.1) 
14 (0.7)
6891 (50.0) 
6470 (48.4) 
415 (3.0)
Birth weight
Grams 
Missing
3226 (565) 
356 (3.1)
3266 (522) 
4 (0.1)
3224 (558) 
14 (0.7)
3216 (565) 
416 (3.0)
Data are means ± SD or n (%) unless stated. ^ gestational age in weeks presented for columns 1, 2 and 3. Offspring age in weeks presented for column 4.
Abbreviations: NMR, nuclear magnetic resonance; BiB, Born in Bradford; BMI, body mass index; kg, kilogram; IMD, index of multiple deprivation (taken from 
2010 national quintiles). There were 9 ethnic groups, of which White British and Pakistani were the main homogeneous groups. The ‘Other’ ethnicity category 
comprises: White Other, Mixed-White and Black, Mixed-White and South Asian, Black, Indian, Bangladeshi or Other ethnicity. 
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metabolomic datasets. The numbers are all based around the 
offspring, for example the number of maternal pregnancy 
metabolite data in any cell refer to the number of offspring 
who have a mother with those samples. There were 11,557 
children from 11,480 pregnancies whose mothers had a preg-
nancy NMR sample. Of these, 6,756 children also had a cord 
Figure 5. Comparisons of glucose concentrations for Metabolon mass spectrometry (MS) with routine glucose oxidase (5A) and 
Nightingale Health© nuclear magnetic resonance (NMR) (5B). R = Pearson correlation coefficient.
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blood sample and 1,981 had at least one measurement from 
either the 12- or 24-month ALL IN subsample. All the mothers 
with a pregnancy MS sample (from either the first or second 
dataset) also have an NMR sample. There were 7,919 children 
in total with an NMR sample in cord blood with 1,275 
of these also having at least one measure from the 12- or 
24-month subsample. Of those with NMR cord blood data, 
2,486 had a mother with MS pregnancy data (from either the 
first or second dataset) and 1,000 have MS cord blood data. 
There were 2,108 children with at least one NMR measure 
at either the 12- or 24-months assessment and of these, 690 
have a mother with MS metabolite measures in pregnancy 
data (from either dataset) and 229 have MS cord blood data. 
Although the exclusion criteria for MS dataset 2 was no prior 
MS metabolomics (Figure 6), there was one mother with 
MS metabolomics in both datasets from different pregnancies.
Using the BiB metabolomic data, including a 
summary of published, ongoing and future 
research using these data
The current BiB metabolite data have been quantified on 
blood samples collected during pregnancy, cord blood at birth 
and in the offspring at 12- and 24-months. These are critical 
time periods for life-course research and the combination of 
Figure 6. Illustrating the flow of participants into the Metabolon datasets in the Born in Bradford cohort. Figure 6A shows 
dataset 1 which includes 1,000 pregnancies and infants with MS metabolomics during pregnancy (26–28 weeks’ gestation (dataset 1a)) and 
in cord blood (dataset 1b). Figure 6B shows dataset 2 which includes 2,000 pregnancies (26–28 weeks’ gestation) with MS metabolomics 
within a case-cohort design. Abbreviations: MS, mass spectrometry; BiB, Born in Bradford; GWAS, genome wide association study; EDTA, 
ethylenediaminetetraacetic acid; HDP, hypertensive disorders of pregnancy; GD, gestational diabetes; GHT, gestational hypertension; PE, 
pre-eclampsia, PTB, preterm birth; CA, congenital anomaly; SB, still birth.
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these data with large amounts of genomic, epigenomic, social 
and health data makes BiB a platform which provides scope for 
unique research opportunities.
Issues for data users
1. Batch effects: The quantified NMR metabolites that have 
been measured in BiB are represented in clinically meaning-
ful units, so can be compared to results from other studies. 
By contrast the Metabolon MS metabolites are quantified in 
relative abundance i.e. in relation to other quantified MS meas-
urements that were run on the same day. The MS Dataset 1 
and Dataset 2 were obtained ~2 years apart and have been 
normalized to different references, so are not directly 
comparable. For example, the value of a specific metabo-
lite from a maternal pregnancy sample in Dataset 1 compared 
to the same metabolite in Dataset 2 may differ because they 
are from different batches. Because of the different selection 
process for the two datasets (Dataset 1 is paired pregnancy-
offspring cord blood samples and Dataset 2 has a case-cohort 
sampling frame) it is not possible to normalize them to the 
same reference. We recommend running analyses sepa-
rately in each of the two datasets and comparing results, then 
meta-analyse if appropriate. In principal components analy-
ses, 37 of the 1,000 women with a pregnancy sample in 
Table 3. Participant characteristics of the mass spectrometry datasets in the BiB cohort.
Dataset 1 
(N = 1,000 
mother/child 
pairs)
Dataset 2 
case-cohorta 
(N = 2,000)
Dataset 2 random 
cohort sample 
onlyb (N = 1,199)
BiB cohort 
(N = 13,776)
Characteristics Category - - -
Maternal age Years 27.5 (5.7) 27.5 (5.7) 26.91 (5.5) 27.3 (5.6)
Missing 0 (0) 0 (0) 0 (0.0) 1445 (10.5)
Maternal parity
Nulliparous 
Multiparous 
Missing
359 (37.0) 
611 (61.1) 
30 (3.0)
745 (37.3) 
1213 (60.1) 
42 (2.1)
433 (37.4) 
725 (60.5) 
41 (3.4)
5101 (37.0) 
7773 (56.4) 
902 (6.5)
Maternal BMI 
(kg/m2) 
Missing
26.7 (6.0) 
36 (3.6)
26.8 (5.9) 
97 (4.9)
25.9 (5.4) 
60 (5.0)
26.0 (5.7) 
3281 (23.8)
Maternal ethnicity
White British 
Pakistani 
Other 
Missing
500 (50.0) 
500 (50.0) 
0 
0
933 (46.7) 
1067 (53.4) 
0 
0
537 (44.8) 
662 (55.2) 
0 
0
5055 (37.8) 
6088 (45.5) 
2223 (16.6) 
410 (3.0)
Index of multiple 
deprivation
Quintile 1 (most deprived) 
Quintile 2 
Quintile 3 
Quintile 4 
Quintile 5 (least deprived) 
Missing
656 (65.6) 
175 (17.5) 
112 (11.2) 
38 (3.8) 
19 (1.9) 
0 (0)
1340 (67.0) 
358 (17.9) 
212 (10.6) 
53 (2.6) 
37 (1.8) 
0 (0)
823 (68.6) 
203 (16.9) 
123 (10.3) 
31 (2.6) 
19 (1.6) 
0 (0)
7566 (66.4) 
2052 (18.0) 
1250 (11.0) 
334 (2.9) 
190 (1.7) 
2384 (17.3)
Offspring sex
Male 
Female 
Missing
512 (51.2) 
488 (48.8) 
0 (0)
1053 (52.7) 
947 (47.3) 
0 (0)
625 (52.1) 
574 (47.9) 
0 (0)
6891 (50.0) 
6470 (48.4) 
415 (3.0)
Offspring 
birthweight
Grams 
Missing
3304 (517) 
0 (0)
3232 (574) 
1 (0)
3318 (486) 
0 (0)
3216 (565) 
416 (3.0)
a This column comprises of the full case-cohort dataset of 2,000 pregnancies. This includes 801 selected cases and the 1,199 random cohort.
b This column includes only the 1,199 random cohort to compare to the full case-cohort with the selected cases.
Data are means ± SD or n (%) unless stated. Abbreviations: BiB, Born in Bradford; BMI, body mass index; kg, kilogram; IMD, index of multiple 
deprivation (taken from 2010 national quintiles). There were nine ethnic groups, of which White British and Pakistani were the main 
homogeneous groups. The ‘Other’ ethnicity category comprises: White Other, Mixed-White and Black, Mixed-White and South Asian, Black, 
Indian, Bangladeshi or Other ethnicity.
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Dataset 1 of MS data had notably different values to those 
in the remaining 963 women, which appeared to be a batch 
effect (see Figure in Extended data11). This is a new finding 
and in previous analyses using these data we have not treated 
these 37 women differently. However, for future analyses we 
would recommend researchers consider running analyses with 
all women and in a sensitivity analysis with these 37 women 
removed.
2. Comparisons with clinical chemistry measurements: We 
have illustrated above strong correlations between glucose 
and lipids measured using clinical chemistry and the NMR 
platform. We found weaker (though directionally consistent) 
associations of BMI with these outcomes measured using 
NMR compared to those with clinical chemistry. In a sec-
ond example, results were consistent between the two methods 
for the associations of pre-eclampsia with glucose and lipids. 
Researchers considering using these data might want to check 
for consistency with associations using the clinical chem-
istry measurement available in BiB. For the MS data we 
were only able to explore correlations with glucose and found 
this to be high between clinical chemistry and MS.
Summary of published research using the BiB 
metabolomics data
We undertook a collaboration between BiB and the UK Pregnan-
cies Better Eating and Activity Trial (UPBEAT), a randomised 
control trial of obese pregnant women (BMI ≥ 30kg/m2)16. 
We found evidence that maternal pregnancy NMR samples 
can improve prediction of pregnancy related disorders16. The 
prediction models consisting of NMR-derived metabolomics 
and established risk factors (maternal age, smoking, BMI, eth-
nicity, and parity) performed better than established risk fac-
tors alone for gestational diabetes, hypertensive disorders of 
pregnancy, small/large for gestational age but not preterm birth 
in BiB. We found directionally consistent, but attenuated, results 
in UPBEAT. The attenuated results in that validation sample 
may reflect the differences between the studies, model overfitting 
in BiB or both.
In other work, we have also shown that that the distributions 
of most of the NMR metabolic measures differed by ethnicity17. 
White European women had higher levels of most lipopro-
tein subclasses, cholesterol, glycerides and phospholipids, 
monosaturated fatty acids, and creatinine but lower levels of 
glucose, linoleic acid, omega-6 and polyunsaturated fatty acids, 
and most amino acids, compared with South Asian women. 
This suggests a more lipidomic response to pregnancy in 
White Europeans and a stronger glycaemic response in South 
Asian women. Higher BMI and having gestational diabetes 
were associated with higher levels of several lipoprotein sub-
classes, triglycerides, and other metabolites in both groups but 
with evidence of weaker magnitudes of association for most 
of these in the South Asian women.
Figure 7. Showing the overlap between the metabolomic datasets in the Born in Bradford cohort presented at the offspring 
level. Abbreviations: NMR, Nuclear magnetic resonance; MS, mass spectrometry.
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In recent collaborations between the BiB cohort and the 
Pregnancy Outcome Prediction study (POPs) using Metabolon 
MS data, we have found evidence that 4’-hydroxyglutamate 
improves prediction of pre-eclampsia compared to clinical 
risk factors alone3 and that a ratio of four metabolites 
(1-(1-enyl-stearoyl)-2-oleoyl-GPC, 1,5-anhydroglucitol,5α-
androstan-3α,17α-diol disulfate and N1,N12-diacetylspermine) 
together with the sFlt-1:PIGF ratio is a better predic-
tor of foetal growth restriction/small for gestational age than 
sFlt-1:PIGF alone4. Initial associations in POPs, a nulliparous, 
largely White European, affluent cohort from the South 
East of England, were validated in BiB. As we have outlined, 
BiB is a cohort of mixed ethnic background, with high levels 
of deprivation and including both nulliparous and multiparous 
women. The consistency of associations between POPs and 
BiB suggests that the prediction accuracy may be widely gen-
eralisable and that the metabolites predicting these outcomes 
may be causally related to them.
Furthermore, combining the MS metabolomics with genomic 
sequence data has enabled the establishment of metabolomic 
consequences of loss of functional rare variants in autozygous 
individuals and the health effects of this loss of function18. 
This has supported the development of the drug lumasiran 
for a rare kidney disease19.
Ongoing and future research
Ongoing work using both the NMR and MS metabolomics 
data will explore how the pregnancy metabolic environment 
relates to fetal growth (using repeat ultrasound scan meas-
ures and birth weight), preterm delivery, and congenital heart 
disease. Potential causal effects in these studies will be explored 
where possible by replication, the use of Mendelian rand-
omization (MR) and triangulation with other types of data 
and study designs. In ongoing work, we are using data 
from both MS datasets to evaluate whether MS-derived 
metabolomics are better predictors of gestational diabetes, 
hypertensive disorders of pregnancy, small and large for ges-
tational age and preterm birth, than risk factors alone (with 
external validation being undertaken in the POPs cohort). 
By combining both NMR and MS data, we are exploring the 
relationships between maternal pregnancy metabolites and their 
offspring cord blood metabolites.
BiB also contributes to metabolomic studies that are being 
undertaken by large collaborative efforts. This includes the 
European H2020 funded LifeCycle project20, in which we 
are exploring exposure to maternal hypertensive disorder of 
pregnancy, gestational diabetes, small and large for gestational 
age and preterm delivery on offspring subsequent meta-
bolic profile. In the Consortium of Metabolomics Studies 
(COMETS)2 there are ongoing projects including trans-ethnic 
genome-wide association analyses (GWAS), and exploring 
effects of BMI, smoking, dietary patterns and hypertension 
on maternal metabolomic profiles.
Discussion and future directions for metabolomic 
analyses in BiB
In this data note we have described multiple datasets with 
NMR and MS metabolomic measures in the BiB cohort. 
The wealth of metabolomics data available in BiB provides 
opportunities for addressing a range of research ques-
tions. In this section, we discuss the strengths and limitations 
of the data, together with some of our insights for using 
these data. We also provide information on plans for future 
measurements of metabolomics in BiB.
A key strength of these datasets is that they are based 
within a cohort that has very detailed information on 13,776 
pregnancies. This includes detailed socioeconomic, educa-
tion, cognitive, and mental and physical health data. We have 
OGTT results and fasting pregnancy blood samples on most 
(83%) of the mothers, genomics (genome wide and sequence) 
data and epigenomics data in maternal pregnancy and 
offspring cord blood. Few studies have pregnancy metabo-
lomics data or OGTT data in numbers of this size. We can 
look at metabolomics and its role in prediction of adverse 
pregnancy/perinatal outcomes and health and develop-
ment in children. BiB has large numbers of South Asian and 
White European families, residing in a city with high levels of 
socioeconomic deprivation. The ethnic diversity allows us to try 
and understand ethnic differences in the developmental origins 
of disease, for example, why South Asian populations have a 
higher risk of type two diabetes and coronary heart disease.
Having access to two metabolomics profiles (NMR and MS) 
is beneficial. The NMR platform mostly consists of lipids 
and lipoproteins, but also provides quantified fatty acids, 
amino acids, glycolysis metabolites, ketone bodies and 
glycoprotein acetyl (an inflammatory marker). It provides 
considerably more information than clinical chemistry meas-
ures that are conventionally measured in cohorts (e.g. glucose, 
total cholesterol, LDLc, HDLc and triglycerides) and at not 
much more cost (~£20 per sample). As a result, we have 
been able to obtain these data on large numbers of women in 
pregnancy, offspring cord blood and in samples taken in off-
spring at 12- and 24- months assessments. By contrast, the 
MS data covers more of the metabolome, including being able 
to assess energy metabolism (which might be important in 
pregnancy) and markers of medications such as paracetamol. 
However, it is more expensive (~£80-£200, depending on 
how many samples are assayed at a time). By having access 
to both datasets here, we can have broader coverage of the 
metabolome21. There are potential uses for both platforms 
– ranging from disease prediction to causal analyses using 
methods such as MR22. Both platforms have been used in 
previous GWAS of metabolites23. As such, BiB could be used 
to explore whether genetic instruments from GWAS can be 
related to NMR or MS metabolites in pregnancy.
Access to this unique metabolomic data is a big advantage 
in BiB. However, we have been unable to validate findings 
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in external cohorts. The work described above cannot be 
replicated because we cannot find other independent studies 
with relevant data17. We hope that this data note will encourage 
other studies to collect similar data in pregnancy, offspring 
cord blood, and in mothers and offspring postnatally 
throughout their life-course.
There are some additional important limitations of the data 
to consider. The impact of these limitations will depend on 
the research question. All the metabolomics datasets were 
collected on subsamples ranging from 11,480 with maternal 
pregnancy NMR samples (83% of the eligible 13,776 
participants) to 1,000 (7%) with MS cord blood samples. Smaller 
sample sizes may be statistically inefficient in some analyses 
and the selection processes (Figure 4 and Figure 6) may 
result in selection bias in some analyses. It is notable and 
provides some reassurance that, even for the smaller sam-
ples, distributions of most characteristics are similar between 
participant groups with different types of metabolomics at 
different time points and the whole cohort (Table 2 and 
Table 3). As Metabolon MS data have been collected only 
on White British and Pakistani women it cannot be assumed 
that analyses with these data would generalize to other ethnic 
groups. BiB cohort participants were largely recruited at the 
OGTT (with a small number recruited after that). This was 
opportunistic as we had no funding for initiating the cohort. 
After consultation with the community and health care 
providers, we established that this would be a suitable time to 
obtain consent, interview pregnant women and collect a fasting 
blood sample for research. However, it means that we are likely 
to have missed women who did not attend the OGTT and were 
not captured later in pregnancy or at delivery, and those who 
delivered pre-term before they attended their OGTT. We 
have previously compared BiB participants to non-BiB births 
occurring between 2007–20118. Summary data from obstetric 
and delivery records were obtained for 11,761 non-BiB births, 
which would include some who moved to Bradford shortly 
before delivery (and would not have been eligible to recruit). 
The comparison showed a small number of differences. BiB 
participants were less likely to include younger mothers (age 
20–24 years) and had a higher proportion of South Asian 
and nulliparous mothers. There were differences in gesta-
tional age and preterm delivery that reflected recruiting BiB 
participants relatively late in pregnancy8. This selection on 
gestational age may introduce selection bias in some BiB 
analyses, including those using the metabolomics data described 
here.
A limitation is that BiB only has pregnancy metabolomics at 
a single time point and does not have pre-pregnancy measure-
ments. Previous research suggests metabolites change upon 
becoming pregnant and then revert to pre-pregnancy levels5 and 
that they change during pregnancy24. Earlier measures would 
be valuable for prediction of future adverse outcomes to 
enable earlier antenatal monitoring and intervention.
This data note has focused on metabolomics data that have 
been quantified by high throughput commercial platforms 
(Nightingale Health© NMR and Metabolon MS). On a small 
subsample of BiB participants (N = 199) NMR urine and 
serum MS blood metabolites have been quantified at Impe-
rial College, London, as part of the HELIX collaboration. 
HELIX aims to identify the human exposome in pregnancy 
and childhood. Metabolite measurements were undertaken 
alongside similar subsamples from five other cohorts (total 
N = 1,192). In all six cohorts, samples were from children 
aged between 6–11 years (BiB participants were mean age 
6.6 years). 44 urine metabolites (24 semi-quantified) and 188 
serum (56 fully quantified) metabolites were measured. We 
have not described these metabolomics datasets here as the 
assays are unique to a small subgroup of BiB participants 
and any research on these participants is best done together 
with the other HELIX cohort subgroups on whom the same 
metabolomic data obtained at the same time and using the same 
methods is available. Further information about the samples 
and methods used can be found elsewhere25.
Up until March 2020, we were undertaking a follow-up of 
BiB parents and offspring, including collecting further blood 
samples with funding available to complete the NMR anal-
yses on offspring and parent serum/plasma collected at 
this follow-up. However, that follow-up stopped on the 16th 
March 2020 when restrictions on normal life due to the 
COVID-19 pandemic began in the UK. At the time of sub-
mitting this paper we do not know when face-to-face data 
collection will be possible to start again and what the best 
plans would be for further blood sample collection. At the rel-
evant time we will discuss different potential scenarios for com-
pleting that planned follow-up with our scientific advisory 
groups. Whatever the decision, we should have some par-
ticipants with serum/plasma NMR measures collected ~8–9 
years after birth. We are also planning to measure metabolites 
on the available maternal pregnancy urine samples. Urine 
metabolites often provide a more accurate measure of dietary 
intake and medicine use than serum/plasma measures and 
would be a valuable addition to the existing datasets described 
here. Any new data will be made available to the wider 
research community.
Data availability
Underlying data
Scientists are encouraged to make use of the BiB data, which 
are available through a system of managed open access.
•  Before you contact BiB, please make sure you 
have read our Guidance for Collaborators. Our BiB 
executive review proposals on a monthly basis and 
we will endeavour to respond to your request as 
soon as possible. You can find out about all of the 
different datasets which are available here. If you 
are unsure if we have the data that you need please 
contact a member of the BiB team (borninbradford@
bthft.nhs.uk).
•  Once you have formulated your request please 
complete the ‘Expression of Interest’ form available 
here and email the BiB research team (borninbradford@
bthft.nhs.uk).
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•  If your request is approved, we will ask you to sign a 
collaboration agreement; if your request involves 
biological samples, we will ask you to complete a 
material transfer agreement.
Extended data
Open Science Framework: Metabolomics data in the Born in 
Bradford cohort. https://doi.org/10.17605/OSF.IO/YST7N11.
This project contains the following extended data:
•  BiB_MS_Dataset1_PCA_Plot.png (Figure showing 
principal component analysis of dataset 1)
•  MS_Metabolite_Details.xlsx (Lists the names and 
details of all metabolites assessed by the Metabolon 
platform in the BiB MS dataset 1a (sheet 1) and BiB 
MS dataset 2 (sheet 2).
•  MS_Quality_Report_Dataset1.pdf (QC report for MS 
dataset 1 from Metabolon)
•  MS_Quality_Report_Dataset2.pdf (QC report for MS 
dataset 2 from Metabolon)
•  NMR_Metabolite_Details.xlsx (Lists the names and 
units of all metabolic traits assessed by the NMR 
platform)
•  NMR_Quality_Report_Cord.pdf (Summarizing quality 
observations in the NMR cord blood dataset)
•  NMR_Quality_Report_Infant.pdf (Summarizing quality 
observations in the NMR infant dataset)
•  NMR_Quality_Report_Pregnancy.pdf (Summarizing 
quality observations in the NMR pregnancy dataset)
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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